Back to results
US 11,951,115 B2Granted
Methods of treating retinal vasculopathies
AssigneeUnity Biotechnology, Inc.
InventorsSharon Klier, Jamie Dananberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.
Claims33
A method of treating a patient suffering from a retinal vasculopathy comprising administering to the patient a therapeutically effective dose of a meglumine salt of a compound of Formula I (Compound-meglumine):
- (R)-5-(4-chlorophenyl)-1-isopropyl-2-methyl-4-(3-(4-(4-((4-((1-(phenylthio)-4-(4-((phosphonooxy)methyl)piperidin-1-yl)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonamido)phenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylic acid,
- wherein the therapeutically effective dose is up to 10 ug of the Compound-meglumine is administered intravitreally (IVT) per eye.
Dependencies are inferred from the claim text.